{"id":"W4399458651","doi":"10.1016/j.ejca.2024.114145","title":"Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer","year":2024,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":false,"ca_institutions":"SickKids Foundation","funders":"National Cancer Institute; Loxo Oncology; Norgine; EUSA Pharma; Y-mAbs Therapeutics; Solving Kids' Cancer; Rally Foundation; Amgen; Eli Lilly and Company; Pediatric Brain Tumor Foundation","keywords":"PI3K/AKT/mTOR pathway; Discovery and development of mTOR inhibitors; Protein kinase B; Cancer; Product (mathematics); Medicine; Cancer research; Internal medicine; Chemistry; Phosphorylation; Signal transduction; Biochemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001292852,0.0006800512,0.0008254156,0.001478114,0.0002311179,0.000908968,0.000735778,0.001648112,0.009387202],"category_scores_gemma":[0.00100107,0.000209003,0.0006489358,0.001084019,0.0003002743,0.001048234,0.0008726054,0.002143796,0.002603375],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006294454,"about_ca_system_score_gemma":0.001849346,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009511812,"about_ca_topic_score_gemma":0.002261835,"domain_scores_codex":[0.9997211,0.00005910702,0.00003287982,0.00002943393,0.0001132297,0.00004419167],"domain_scores_gemma":[0.9995824,0.0001374701,0.0001100668,0.00001083321,0.00009093941,0.00006835957],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001935659,0.0001417013,0.0001232679,0.008370458,0.00006062586,0.0002732665,0.00003382321,0.0002801467,0.002464104,0.005686716,0.1071425,0.87523],"study_design_scores_gemma":[0.0001094294,0.0001859177,0.0004611483,0.002688045,0.00007713414,0.000598683,0.00001538849,0.00008785973,0.0005772452,0.0009772799,0.9942123,0.000009460515],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0003620802,0.9898616,0.0005508513,0.001968828,0.001296412,0.00005297952,0.0001692413,0.00004233873,0.005695575],"genre_scores_gemma":[0.002670425,0.9875906,0.001280086,0.002015435,0.0008696649,0.00007017646,0.0002624621,0.000009526632,0.005231697],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.009387202,"threshold_uncertainty_score":0.0314033,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01731181423656138,"score_gpt":0.3037225914434496,"score_spread":0.2864107772068882,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}